Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes

Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in patients with type 2 diabetes (T2D). Historical concerns about cardiovascular (CV) risks associated with certain glucose-lowering medications gave rise to the introduction of cardiovascular outcomes trials (CVOTs). Initi...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Melanie J., Drexel, Heinz, Jornayvaz, François R., Pataky, Zoltan, Seferović, Petar M., Wanner, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351217/
https://www.ncbi.nlm.nih.gov/pubmed/35927730
http://dx.doi.org/10.1186/s12933-022-01575-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351217/
https://www.ncbi.nlm.nih.gov/pubmed/35927730
http://dx.doi.org/10.1186/s12933-022-01575-9

Ejemplares similares